Biovail to Present at American College of Cardiology in Chicago on March 29 & 30, 2003.Business Editors/Health/Medical Writers TORONTO--(BUSINESS WIRE)--March 28, 2003 Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF)(TSX:BVF) announced today that Biovail is involved in the following two events at the American College of Cardiology The American College of Cardiology (ACC) is a nonprofit medical association established in 1949 to educate, research and influence health care public policy. The president for the 2006–2007 year is Steven E. Nissen. [1] The organization has 39 chapters in the U.S. (ACC) in Chicago, Illinois on March 29th and March 30th: Dr. Richard Conti, Professor of Medicine, Cardiology at the University of Florida University of Florida is the third-largest university in the United States, with 50,912 students (as of Fall 2006) and has the eighth-largest budget (nearly $1.9 billion per year). UF is home to 16 colleges and more than 150 research centers and institutes. College of Medicine and Dr. Stephen P. Glasser, Professor of Epidemiology and Director of Graduate Studies in Clinical Research, University of Minnesota (body, education) University of Minnesota - The home of Gopher. http://umn.edu/. Address: Minneapolis, Minnesota, USA. , will present a continuing medical education continuing medical education See CME. symposium session entitled "Optimizing Cardiovascular Management: New Approaches to the Treatment of Angina" on Saturday March 29, 2003, from noon to 2PM in the Chicago Ballroom (Salon E) of the Chicago Marriott Downtown Hotel. An ACC poster session - "Efficacy and Safety of a Once-daily Graded-release Diltiazem HCl Formulation Dosed at Bedtime (10 PM) Compared to Placebo and to Morning Dosing (8 AM) in Chronic Stable Angina chronic stable angina Cardiology The most common form of angina, characterized by chest discomfort due to myocardial ischemia, and unaccompanied by myocardial necrosis; the cause of pain is uncertain, possibly substances released during transient ischemia–eg, Pectoris" - will be presented by Dr. Glasser, the study's primary author, on Sunday March 30, 2003, from noon to 2PM in Hall A of McCormick Place, in Chicago, Illinois. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion